10.14.15
Rancho Cordova, Calif.-based Cesca Therapeutics Inc., an autologous cell-based regenerative medicine company, has partnered with St. Jude Children’s Research Hospital in Memphis, Tenn.
The agreement calls for the hospital to evaluate a prototype for a new Cellwerks device under Cesca’s “Early Technology Access Program.” The new device will specifically address the need for reduced red blood cell content in stem cell preparation for patients at risk of major blood-type mismatches.
Commercial launch of the new device is expected in late 2016.
“This collaboration with St. Jude Children’s Research Hospital is a strategic next-step to Cesca’s recent announcements addressing life-saving areas of need in hematology/oncology,” said Mitchel Sivilotti, senior vice president and chief biologist at Cesca Therapeutics. “We are in a unique position to develop and commercialize rapid cell isolation technology for multiple clinical applications and view major blood-type mismatch as one of the cornerstones of our Cellwerks portfolio. This project, in addition to recent developments in our Haplo-identical Transplant program in India, represents a robust approach to addressing this growing, high value space.”
The agreement calls for the hospital to evaluate a prototype for a new Cellwerks device under Cesca’s “Early Technology Access Program.” The new device will specifically address the need for reduced red blood cell content in stem cell preparation for patients at risk of major blood-type mismatches.
Commercial launch of the new device is expected in late 2016.
“This collaboration with St. Jude Children’s Research Hospital is a strategic next-step to Cesca’s recent announcements addressing life-saving areas of need in hematology/oncology,” said Mitchel Sivilotti, senior vice president and chief biologist at Cesca Therapeutics. “We are in a unique position to develop and commercialize rapid cell isolation technology for multiple clinical applications and view major blood-type mismatch as one of the cornerstones of our Cellwerks portfolio. This project, in addition to recent developments in our Haplo-identical Transplant program in India, represents a robust approach to addressing this growing, high value space.”